TMPRSS4 Drives Angiogenesis in Hepatocellular Carcinoma by Promoting HB‐EGF Expression and Proteolytic Cleavage. Issue 3 (30th June 2020)

• Record Type: Journal Article
• Authors: Dong, Zhao‐Ru; Sun, Dong; Yang, Ya‐Fei; Zhou, Wei; Wu, Rui; Wang, Xiao‐Wei; Shi, Kai; Yan, Yu‐Chuan; Yan, Lun‐Jie; Yao, Cheng‐Yu; Chen, Zhi‐Qiang; Zhi, Xu‐Ting; Li, Tao
• Is Part Of: Hepatology. Volume 72:Issue 3(2020)
• Page Start: 923
• Page End: 939
• Publication Date: 2020-06-30
• Subjects: Heart -- Diseases -- Nursing -- Periodicals; Lungs -- Diseases -- Nursing -- Periodicals; Intensive care nursing -- Periodicals; Foie -- Maladies -- Périodiques; 616.362
• DOI: 10.1002/hep.31076
• Languages: English
• ISSNs: 0270-9139

Abstract

Abstract : Background and Aims: Heparin‐binding epidermal growth factor (HB‐EGF), a member of the epidermal growth factor family, plays a pivotal role in the progression of several malignancies, but its role and regulatory mechanisms in hepatocellular carcinoma (HCC) remain obscure. Here, we report that transmembrane protease serine 4 (TMPRSS4) significantly enhanced the expression and proteolytic cleavage of HB‐EGF to promote angiogenesis and HCC progression. Approach and Results: A mechanistic analysis revealed that TMPRSS4 not only increased the transcriptional and translational levels of HB‐EGF precursor, but also promoted its proteolytic cleavage by enhancing matrix metallopeptidase 9 expression through the EGF receptor/Akt/mammalian target of rapamycin/ hypoxia‐inducible factor 1 α signaling pathway. In addition, HB‐EGF promoted HCC proliferation and invasion by the EGF receptor/phosphoinositide 3‐kinase/Akt signaling pathway. The level of HB‐EGF in clinical samples of serum or HCC tissues from patients with HCC was positively correlated with the expression of TMPRSS4 and the microvessel density, and was identified as a prognostic factor for overall survival and recurrence‐free survival, which suggests that HB‐EGF can serve as a potential therapeutic target for HCC. More importantly, we provide a demonstration that treatment with the HB‐EGF inhibitor cross‐reacting material 197 alone or in combination with sorafenib can significantly suppress angiogenesis and HCC progression. Conclusions: HB‐EGF can be regulated by TMPRSS4 to promote HCC proliferation, invasion, and angiogenesis, and the combination of the HB‐EGF inhibitor cross‐reacting material 197 with sorafenib might be used for individualized treatment of HCC.